Tyra Biosciences, Inc. (NASDAQ:TYRA) Position Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 2.2% during the third quarter, Holdings Channel.com reports. The firm owned 173,737 shares of the company’s stock after acquiring an additional 3,792 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Tyra Biosciences were worth $4,085,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of TYRA. Perceptive Advisors LLC raised its stake in shares of Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in shares of Tyra Biosciences during the second quarter valued at about $4,232,000. Ensign Peak Advisors Inc bought a new stake in shares of Tyra Biosciences during the second quarter valued at about $3,047,000. American Century Companies Inc. raised its stake in shares of Tyra Biosciences by 582.9% during the second quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after purchasing an additional 145,346 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Tyra Biosciences during the third quarter valued at about $491,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Trading Down 1.5 %

Shares of TYRA opened at $14.94 on Friday. The business’s 50-day moving average price is $18.61 and its 200 day moving average price is $19.62. The stock has a market capitalization of $755.96 million, a P/E ratio of -9.28 and a beta of 1.01. Tyra Biosciences, Inc. has a 1-year low of $11.24 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). On average, research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling

In other Tyra Biosciences news, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total transaction of $179,131.26. Following the transaction, the director now owns 472,207 shares of the company’s stock, valued at $7,635,587.19. The trade was a 2.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Todd Harris sold 5,698 shares of Tyra Biosciences stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the transaction, the chief executive officer now directly owns 1,496,729 shares in the company, valued at approximately $36,385,481.99. This trade represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 101,050 shares of company stock valued at $2,235,492. 15.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

TYRA has been the topic of a number of research analyst reports. HC Wainwright lowered their target price on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Oppenheimer lifted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Wedbush reaffirmed an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a report on Friday, October 25th. Finally, Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $31.00.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.